Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750589 | 0.88 | CA2 (0.48) | CA2KDM4EALDH1A1 | |
| SCHEMBL750645 | 0.81 | CA2 (0.51) | CA2POLBKDM4EALDH1A1HDAC3 | |
| SCHEMBL8907294 | 0.78 | CA2 (0.49) | CA2POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL777369 | 0.77 | CA2 (0.71) | CA2POLBKDM4EALDH1A1HDAC3 | |
| SCHEMBL11758463 | 0.76 | CA2 (0.46) | CA2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL3626579 | 0.75 | CA2 (0.52) | CA2ALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL2031618 | 0.75 | CA2 (0.58) | CA2POLBKDM4EALDH1A1HDAC3 | |
| SCHEMBL7172000 | 0.74 | CA2 (0.45) | CA2POLBKDM4EALDH1A1HDAC3 | |
| SCHEMBL10995947 | 0.74 | HDAC1 (0.63) | CA2POLBKDM4EALDH1A1HDAC3 | |
| SCHEMBL1171862 | 0.74 | MGLL (0.61) | CA2POLBKDM4EALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213166-B1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GMBH (DE) | 2012-03-21 | — | — | EP | claimed |
| EP-2213166-A1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GmbH (DE) | 2010-08-04 | — | — | EP | claimed |
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | THOR GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2216372-B1 | Compounds for preventing Ghost odour | THOR GMBH (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8287631-B2 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2213166-B1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2216372-A1 | Compounds for preventing Ghost odour | THOR GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2213166-A1 | Biocidal compounds containing 2-methylisothiazolin-3-one and a haloalkylsulfone | THOR GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | THOR GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100186631-A1 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189811-A1 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone | MBTD1, MPST, B2M | CA2 1575/4885POLB 2033/4885KDM4E 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.